CryoLife, Inc. (NYSE:CRY) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $40-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.43. The company issued revenue guidance of $188-192 million, compared to the consensus revenue estimate of $189.31 million.
Shares of CryoLife, Inc. (CRY) opened at 19.05 on Friday. CryoLife, Inc. has a one year low of $14.02 and a one year high of $20.30. The company has a market capitalization of $637.15 million, a PE ratio of 57.73 and a beta of 0.97. The company’s 50-day moving average is $19.18 and its 200-day moving average is $17.98.
CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same period in the previous year, the business posted $0.13 EPS. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.
A number of equities research analysts recently issued reports on CRY shares. Zacks Investment Research upgraded CryoLife from a hold rating to a buy rating and set a $21.00 price objective on the stock in a research note on Thursday, June 8th. Northland Securities reiterated a buy rating and set a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Finally, BidaskClub cut CryoLife from a buy rating to a hold rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $22.00.
In other news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now directly owns 112,282 shares in the company, valued at $2,245,640. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.00% of the company’s stock.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.